Progress in the design of inhibitors of coagulation factor Xa

Drugs of the Future

Volumn 24, Issue 7, 1999, Pages 771-787

  Ewing, William R ^a   Pauls, Henry W ^a   Spada, Alfred P ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; BLOOD CLOTTING FACTOR 10A INHIBITOR;

DRUG ACTIVITY; DRUG DESIGN; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; REVIEW;

EID: 0032831727     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.07.858624     Document Type: Review

References (148)

1. Bick, R.L., Kaplan, H. Syndromes of thrombosis and hypercoagulability. Congenital and acquired causes of thrombosis. Med Clin North Am 1998, 82: 409-58.
2. Turpie, A.G.G. Clinical potential of antithrombotic drugs in coronary syndromes. Am J Cardiol 1998, 82: 11L-4.
3. Dobesh, P.P., Latham, K.A. Advancing the battle against acute ischemic syndromes: A focus on the GPIIb-IIIa inhibitors. Pharmacotherapy 1998, 18: 663-85.
4. Adgey, A.A.J. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Eur Heart J 1998, 19: D10-21.
5. Kaiser, B. Thrombin and factor Xa inhibitors. Drugs Fut 1998, 23: 423-36.
6. Kaiser, B., Callas, D., Walenga, J.M., Fareed, J. Synthetic and recombinant antithrombin drugs. Exp Opin Invest Drugs 1998, 7: 963-85.
7. Chi, L., Rogers, K.L., Uprichard, A.C.G., Gallagher, K.P. The therapeutic potential of novel anticoagulants. Exp Opin Invest Drugs 1997, 6: 1591-622.
8. Sanderson, P.E.J., Naylor-Olsen, A.M. Thrombin inhibitor design. Curr Med Chem 1998, 5: 289-304.
9. Vacca, J.P. Thrombosis and coagulation. Ann Rep Med Chem 1998, 33: 81-90.
10. Gardell, S.J., Sanderson, P.E.J. Novel anticoagulants based on direct inhibition of thrombin and factor Xa. Coronary Artery Dis 1998, 9: 75-81.
11. Verstraete, M. Direct thrombin inhibitors. Appraisal of the antithrombotic/hemorrhagic balance. Thromb Haemost 1997, 78: 357-63.
12. Eriksson, B.I., Wille-Jorgensen, P., Kalebo, P. et al. A comparison of recombinant hirudin with a low-molecular weight heparin to prevent thromboembolic complications after total hip replacement. New Engl J Med 1997, 337: 1329-35.
13. Prager, N.A., Abendschein, D.R., McKenzie, C.R., Eisenberg, P.R. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 1995, 92: 962-7.
14. Furie, B., Furie, B.C. Molecular basis of blood coagulation. In: Hematology: Basic Principles and Practices. Hoffman, R., Benz, E.J., Shattil, S.J., Furie, B., Cohen, H.J., Silberstein, L.E. (Eds.). Churchill Livingstone: New York 1995, 1566-87.
15. De La Cadena, R.A., Wachtfogel, Y.T., Coleman, R.W. Contact activation pathway: Inflammation and coagulation. In: Hemostatis and Thrombosis: Basic Principles and Clinical Practice. Coleman, R.W., Hirsh, J., Mander, V.J., Salzman, E.W. (Eds.). J.B. Lipincott Co.: Philadelphia 1994, 219-40.
16. Nemerson, Y. The tissue factor pathway of blood coagulation. In: Hemostatis and Thrombosis: Basic Principles and Clinical Practice. Coleman, R.W., Hirsh, J., Mander, V.J., Salzman, E.W. (Eds.). J.B. Lipincott Co.: Philadelphia 1994, 81-93.
17. Kirchhofer, D., Banner, D.W. Molecular and structural advances in tissue factor-dependent coagulation. TCM 1997, 7: 316-23.
18. Katafatis, M., Swords, N.A., Rand, M.D., Mann, K.G. Membrane-dependent reactions in blood coagulation: Role of the vitamin K-dependent enzyme complexes. Biochim Biophys Acta 1994, 1227: 113-29.
19. Weitz, J.L., Hudoba, M., Massel, D., Maraganore, J., Hirsh, J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin-III independent inhibitors. J Clin Invest 1990, 86: 962-8.
20. Ofosu, F.A., Longbin, L., Freedman, J. Control mechanisms in thrombin generation. Semin Thromb Hemost 1996, 22: 303-8.
21. Jamieson, G.A. Pathophysiology of platelet thrombin receptors. Thromb Haemost 1997, 78: 242-6.
22. Esmond, C.T. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 1995, 9: 946-55.
23. Sadler, J.E. Thrombomodulin structure and function. Thromb Haemost 1997, 78: 392-5.
24. Castellino, F.J. Human protein C and activated protein C: Components of the human anticoagulation system. TCM 1995, 5: 55-62.
25. Bajaj, M.S., Ameri, k, Bajaj, S.P. Tissue factor pathway inhibitor-A regulator of tissue factor induced coagulation. In: Anticoagulants: Physiologic, Pathologic and Pharmacologic. Green, D. (Ed.). CRC Press: Boca Raton 1994, 41-65.
26. Bombeli, T., Muller, M., Haeberli, A. Anticoagulant properties of the vascular endothelium. Thromb Haemost 1997, 78: 408-23.
27. Michiels, J.J., Hamulyak, K. Laboratory diagnosis of hereditary thrombophilia. Semin Thromb Hemost 1998, 24: 309-20.
28. Rosenberg, R.P., Bauer, K.A. The heparin-antithrombin system: A natural anticoagulant mechanism. In: Hemostatis and Thrombosis: Basic Principles and Clinical Practice. Coleman, R.W., Hirsh, J., Mander, V.J., Salzman, E.W. (Eds.). J.B. Lipincott Co.: Philadelphia 1994, 837-60.
29. Hirsh, J. Heparin. New Engl J Med 1991, 324: 156-74.
30. Schussheim, A.E., Fuster, V. Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac disease. Prog Cardiovasc Dis 1997, 40: 205-38.
31. Hogg, P.J., Jackson, C.M. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy. Proc Natl Acad Sci USA 1989, 86: 3619-23.
32. Weitz, J.I., Leslie, B., Hudoba, M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998, 97: 544-52.
33. Brieger, D.B., Mak, K-H., Kottke-Marchant, K., Topol, E.J. Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998, 31: 1449-51.
34. Theroux, P., Waters, D., Lam, J., Juneau, M., McCans, J. Reactivation of unstable angina after the discontinuation of heparin. New Engl J Med 1992, 327: 141-5.
35. Granger, C.B., Miller, J.M., Bovill, E.G. et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995, 91: 1929-35.
36. Weitz, J.I. Low-molecular weight heparins. New Engl J Med 1997, 337: 688-98.
37. Turpie, A.G. Pharmacology of the low-molecular weight heparins. Am Heart J 1998, 135: S329-35.
38. Frydman, A. Low-molecular-weight heparins: An overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 1996, 26: 24-38.
39. Cohen, M., Demers, C., Garfinkel, E.P. et. al. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease. New Engl J Med 1997, 337: 447-52.
40. Haas, S. The role of low-molecular-weight heparins in the prevention of venous thrombosis in surgery with special reference to enoxaparin. Hemostasis 1996, 26: 39-48.
41. Fareed, J., Jeske, W., Hoppensteadt, D., Clarizio, R., Walenga, J.M. Low-molecular-weight heparins: Pharmacologic profile and product differentiation. Am J Cardiol 1998, 82: 3L-10.
42. Colligon, F. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995, 73, 630-40.
43. Freedman, M.D. Warfarin and other "anti"-vitamin K anticoagulants. Pharmacodynamics and clinical use. Am J Ther 1996, 3: 771-83.
44. Freedman, M.D. Oral anticoagulants: Pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol 1992, 32: 196-209.
45. Triplett, D.A. Current recommendations for warfarin therapy: Use and monitoring. Med Clin North Am 1998, 82: 601-11.
46. Berry, C.N., Girardot, C., Lecoffre, C., Lunven, C. Effects of the synthetic thrombin inhibitor argatroban on fibrin-or clot-incorporated thrombin: Comparison with heparin and hirudin. Thromb Haemost 1994, 72: 381-6.
47. Cohen, M. New therapies for unstable angina and non-Q-wave myocardial infarction: Recent clinical trials. Am Heart J 1998, 135: S343-52.
48. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) II investigators. Circulation 1994, 90: 1631-7.
49. Antman, E.M. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994, 90: 1624-30.
50. A comparison of recombinant huridin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. New Engl J Med 1996, 335: 775-82.
51. Antman, E.M. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996, 94: 911-21.
52. A low molecular weight, selective thrombin inhibitor inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose finding study. Thrombin Inhibition in Myocardial Ischemia (TRIM) study group. Eur Heart J 1997, 18: 1416-25.
53. Andersen, K., Dellborg, M. Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group. Am J Cardiol 1998, 81: 939-44.
54. Hursting, M.J., Alford, K.L., Becker, J.C. et al. Novastan (brand of argatroban): A small-molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997, 23: 503-16.
55. Gold, H.K., Torres, F.W., Garabedian, H.D. et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993, 21: 1039-47.
56. Market Letter 1997, 24: 18.
57. Kimball, S.D. Challenges in the development of orally bioavailable thrombin active site inhibitors. Blood Coagul Fibrinolysis 1995, 6: 511-9.
58. Sanderson, P.E.J., Lyle, T.A., Cutrona, K.J. et al. Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopryidinone or 3-aminopyrazinone acetamide peptidomimetic templates. J Med Chem 1998, 41: 4466-74.
59. Anand, S.S., Yusuf, S., Pogue, J., Weitz, J.I., Flather, M. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: Organization to Assess Strategies for Ischemic Syndromes (OASIS) pilot study results. Circulation 1998, 98: 1064-70.
60. Al-Obeidi, F., Ostrem, J. Factor Xa inhibitors by classical and combinatorial chemistry. Drug Discov Today, 1998, 3: 223-31.
61. Scarborough, R.M. Anticoagulant strategies targeting thrombin and factor Xa. Ann Rep Med Chem 1995, 30: 71-9.
62. Davie, E.W., Fujikawa, K., Kisiel, W. The coagulation cascade: Interaction, maintenance and regulation. Biochemistry 1991, 30: 10363-70.
63. Morita, T., Jackson, C.M. Preparation and properties of derivatives of bovine factor X and Xa from which the γ-carboxyglutamic acid containing domain has been removed. J Biol Chem 1986, 261: 4015-23.
64. Leytus, S.P., Chung, D.W., Kiesiel, W., Kurachi, K., Davie, E.W. Characterization of a cDNA coding for human factor X. Proc Natl Acad Sci USA 1984, 81: 3699-702.
65. Tulinsky, A., Padmanbhan, K., Padmanbhan, K.P. et al. Structure of human des(1-45) factor Xa at 2.2 Å resolution. J Mol Biol 1993, 232: 947-66.
66. Warshel, A., Naray-Szabo, G., Sussman, F., Hwang, J.-K. How do serine proteases really work? Biochemistry 1989, 28: 3629-37.
67. Kraut, J. Serine proteases: Structure and mechanism of catalysis. Ann Rev Biochem 1977, 46: 331-58.
68. Mehdi, S. Synthetic and naturally occurring protease inhibitors containing an electrophilic carbonyl group. Bioorg Chem 1993, 21: 249-59.
69. Laskowski, M., Kato, I. Protein inhibitors of proteinases. Ann Rev Biochem 1980, 49: 593-626.
70. Wei, A., Alexander, R.S., Duke, J., Ross, H., Rosenfeld, S.A., Chang, C.H. Unexpected binding mode of tick anticoagulant peptide complexed to bovine factor Xa. J Mol Biol 1998, 283: 147-54.
71. Walter, J., Steigemann, W., Singh, T.P., Bartunik, H., Bode, W., Huber, R. On the disordered activation domain in trypsinogen: Chemical labeling and low-temperature crystallography. Acta Crystallogr Sect B 1982, 38: 1462-72.
72. Bode, W., Mayr, I., Baumann, U., Huber, R., Stone, S., Hofseenge, J. The refined 1.9 Å crystal structure of human α-thrombin: Interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 1989, 8: 3467-75.
73. Branstetter, H., Kuhne, A., Bode, W. et al. X-ray structure of active site inhibited clotting factor Xa. J Biol Chem 1996, 271: 29988-92.
74. Stubbs, M.T., Huber, R., Bode, W. Crystal structures of factor Xa specific inhibitors in complex with trypsin: Structural grounds for inhibition of factor Xa and selectivity against thrombin. FEBS Lett 1995, 375: 103-7.
75. Phillips, G.B., Buckman, B.O., Davey, D.D. et al. Discovery of N-[2-[5-[amino(imino)methyl]-2-hydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin- 4-yl]-N-methylglycine (ZK-807834): A potent and orally active inhibitor of the blood coagulation enzyme factor Xa. J Med Chem 1998, 41: 3557-62.
76. Cacciola, J., Fevig, J.M., Alexander, R.S., Stouten, P.F.W. Synthesis and activity studies of conformationally restricted α-keto amide factor Xa inhibitors. 216th ACS Natl Meet (Aug 23-28, Boston) 1998, MEDI 78.
77. Furie, B., Bing, D.A., Feldman, R.J., Robinson, D.J., Burnier, J.P., Furie, B.C. Computer-generated models of blood coagulation factor Xa, factor IXa and thrombin based upon structural homology with other serine proteases. J Biol Chem 1982, 257: 3875-82.
78. Lin, Z., Johnson, M.E. Proposed cation-π mediated binding by factor Xa: A novel enzymatic mechanism for molecular recognition. FEBS Lett 1995, 370: 1-5.
79. Powers, J.C. Halomethylketone inhibitors of proteolytic enzymes. In: Chemistry and Biochemistry of Amino Acids, Peptides and Proteins. Weinstein, B. (Ed.). Marcel Dekker: New York 1977, 4: 65-178.
80. Kettner, C.A., Shaw, E. Inactivation of trypsin-like enzymes with peptides of arginine chloromethyl ketones. Method Enzymol 1981, 80: 826-42.
81. Demuth, H.U. Recent developments in inhibiting cysteine and serine proteases. J Enzyme Inhib 1990, 3: 249-78.
82. Mann, K.G., Nesheim, M.E., Church, W.K, Haley, P. Drosjmaswamu, S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990, 76: 1-16.
83. Hofmann, K.J., Nutt, E.M., Dunwiddie, C.T. Site directed mutagenesis of the leech-derived factor Xa inhibitor antistasin. Biochem J 1992, 287: 943-9.
84. Stanssens, P., Bergum, P.W., Gansemans, Y. et al. Anticoagulant repertoire of the hookworm Ancyclostoma caninum. Proc Natl Acad Sci USA 1996, 93: 2149-54.
85. Girard, T.J., Warren, L.A., Novotny, W.F. et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989, 338: 518-20.
86. Ripka, W., Brunck, T., Stanssens, P. et al. Strategies in the design of inhibitors of serine proteases of the coagulation cascade-factor Xa. Eur J Med Chem 1995, 30: 87s-100.
87. Brunck, T.K., Webb, T.R., Ripka, W.C. Preparation of peptide aldehydes as specific inhibitors of factor Xa. WO 9413693.
88. Marlowe, C.K., Nyman, M.C., Gunn, A.C., Sinha, U., Scarborough, R.M. Design, synthesis and structure-activity relationship of a series of arginine ketoamide factor Xa inhibitors II: Structures based on the (D)-arg-gly-arg tripeptide sequence. 213th ACS Natl Meet (Apr 13-18, San Francisco) 1997, MEDI 99.
89. Marlowe, C.K., Scarborough, R.M., Laibelman, A.M., Sinha, U., Zhu, B. Preparation of ketoheterocyclic peptides as inhibitors of factor Xa inhibitors. WO 9640744.
90. Stürzebecher, J., Markwardt, F., Wagner, G., Walsmannn, P. Synthetic inhibitors of serine proteinases. 13. Quantitative structure activity relationships in the inhibition of trypsin, plasmin and thrombin by 4-amidinophenyl compounds with ketone structures. Acta Biol Med Ger 1976, 35: 1665-76.
91. Zhu, B.Y., Scarborough, R.M. Preparation of peptides as factor Xa inhibitors. WO 9816547.
92. Zhu, B.Y., Scarborough, P.M. Preparation of heterocyclyl peptides as factor Xa inhibitors WO 9816524.
93. Berryman, K.A., Doherty, A.M., Edmunds, J.J. Siddiqui, M.A. Preparation of pyrrolo[1,2-a]pyrazine-1,4-dione serine protease inhibitors. WO 978706.
94. Semple, J.E., Rowley, D.C., Brunck, T.K. et al. Design, synthesis and evolution of a novel, selective and orally bioavailable class of thrombin inhibitors. P1-arginal derivatives incorporating P3-P4 lactam sulfonamide moieties. J Med Chem 1996, 39: 4527-30.
95. Wallis, R.B. Inhibitors of coagulation factor Xa: From macromolecular beginnings to small molecules. Curr Opin Ther Pat Aug 1993.
96. Ostem J.A., Al-Obeidi, F., Safer, P. et al. Discovery of a novel, potent, and specific family of factor Xa inhibitors via combinatorial chemistry. Biochemistry 1998, 37: 1053-9.
97. Ripka, W.C. Design of antithrombotic agents directed at factor Xa. In: Structure Based Drug Design. Veerapandian, P. (Ed.). Marcel Dekker: New York 1997, 265-94.
98. Tidwell, R.P, Webster, W.P., Shaver, S.R., Geratz, J.D. Strategies for anti-coagulation with synthetic protease inhibitors: Xa inhibitors versus thrombin inhibitors. Thromb Res 1980, 19: 339-49.
99. Stürzebecher, J., Stürzebecher, U., Vieweg, H., Wagner, G., Hauptmann, J., Markwardt, F. Synthetic inhibitors of bovine factor Xa and thrombin: Comparison of their anticoagulant efficiency. Thromb Res 1989, 54: 245-52.
100. Nagahara, T., Yokoyama, Y., Inamura, K. et al. Dibasic (amidinoaryl)propionic acid derivatives as novel blood coagulation factor Xa inhibitors. J Med Chem 1994, 37: 1200-7.
101. Katakura, S., Nagahara, T., Hara, T., Iwamoto, M. A novel factor Xa inhibitor: Structure-activity relationships and selectivity between factor Xa and thrombin. Biochem Biophys Res Commun 1993, 197: 965-72.
102. Hara, T., Yokoyama, A., Ishihara, H., Yokoyama, Y., Nagahara, T., Iwamoto, M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor of factor Xa. Thromb Haemost 1994, 71: 314-9.
103. Markwardt, F., Hauptmann, M., Richter, M., Richter, P. Tierexperimentelle untersuchungen zur pharmakokinetic von 4-amidinophenylbrenztraubensaure. Pharmazie 1979, 34: 178-81.
104. Hirayama, F., Koshio, H., Taniuhi, Y. et al. Synthesis and structure-activity relationships of N-[(7-amidino-2-naphthyl)-methyl]amide derivatives: Potent and orally active fXa inhibitors. 214th ACS Natl Meet (Sept 7-11, Las Vegas) 1997, MEDI 49.
105. Taniuchi, Y., Sakai, Y., Hisamich, N. et al. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa. Thromb Haemost 1998, 79: 543-8.
106. Sato, K., Kawasaki, T., Taniuchi, Y., Hirayama, F., Koshio, H., Matsumoto, Y. YM-60828, a novel factor Xa inhibitor: Separation of its antithrombotic effects from its prolongation of bleeding time. Eur J Pharmacol 1997, 339: 141-6.
107. Kawasaki, T., Sato, K., Sakai, Y. et al. Comparative studies of an orally active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis. Thromb Haemost 1998, 79: 410-6.
108. Kucznierz, R., Grams, F., Leiert, H., Marzenell, K., Engh, R.A., von der Saal, W. Tetrahydro-isoquinoline-based factor Xa inhibitors. J Med Chem 1998, 41: 4983-94.
109. Nomoto, T, Kyoko, H., Hiroshi, K., Sato, S., Miyaji, M., Takaenoki, Y. Preparation of isoindolinyl bicyclic aromatic amidines as anticoagulants. JP 10017549.
110. Kucznierz, R., Leinert, H., von der Saal, W., Niedlein, R., Kehr, C. Novel phosphonates, process for their preparation and pharmaceutical compositions. EP 842941.
111. Gabriel, B., Stubbs, M.T., Bergner, A. et al. Design of benzamidine-type inhibitors of factor Xa. J Med Chem 1998, 41: 4240-50.
112. Shaw, K.J., Guilford, W.J., Dallas, J.L. et al. (Z,Z)-2,7-Bis(4-amidinobenzyldidines)cyclohetan-1-one: Identification of a highly active inhibitor of blood coagulation factor Xa. J Med Chem 1998, 41: 3551-6.
113. Shaw, K.J., Arnaiz, D.O., Buckman, B.O. et al. Development of potent and selective and orally available factor Xa inhibitors. 215th ACS Natl Meet (Mar 29-Apr 2, Dallas) 1998, MEDI 201.
114. Morser, J. Efficacy and safety of BX-807834, a novel Xa inhibitor. In: IBC's 9th Annual International Symposium on Advances in Anticoagulant, Antithrombotic and Thrombolytic Drugs (Sept 10-12, Cambridge) 1998.
115. Walsmann, P. Inhibition of serine proteinases by benzamidine derivatives. Acta Biol Med Ger 1977, 36: 1931-7.
116. Buckman, B.O., Mohan, R.M., Koovakkat, S., Liang, A., Trinh, L., Morrissey, M.M. Design, synthesis and biological activity of novel purine and bicyclic pyrimidine factor Xa inhibitors. Bioorg Med Chem Lett 1998, 8: 2235-40.
117. Kochanny, M.J., Morrissey, M.M., Ng, H.P. Thio acid-derived monocyclic N-heterocyclics as anticoagulants. WO 9815547.
118. Chou, Y.L., Guilford, W.J., Koovakkat, S. et al. Design and biological activity of novel factor Xa inhibitors. 10. Optimization of dibenzyl cyclic urea analogs. 215th ACS Natl Meet (Mar 29-Apr 2, Dallas) 1998, MEDI 130.
119. Arnaiz, D.O., Chou, Y.L., Mohan, R. et al. Design and biological activity of novel factor Xa inhibitors. 8. Indole-based inhibitors. 215th ACS Natl Meet (Mar 29-Apr 2, Dallas) 1998, MEDI 128.
120. Zhao, Z., Shaw, K.J., Whitlow, M. et al. Design, synthesis and biological activity of novel factor Xa inhibitors. 7. Tetrahydrocarboline and carbazole-based inhibitors. 215th ACS Natl Meet (Mar 29-Apr 2, Dallas) 1998, MEDI 127.
121. Greidel, B.D., Arnaiz, D.O., Sakata, S.T. et al. Design, synthesis and biological activity of novel factor Xa inhibitors. 9. Benzimidazole-based analogs. 215th ACS Natl Meet (Mar 29-Apr 2, Dallas) 1998, MEDI 129.
122. Kamata, K., Kawamoto, H., Honma, T., Iwama, T., Kim, S.H. Structural basis for chemical inhibition of human blood coagulation factor Xa. Proc Natl Acad Sci USA 1998, 95: 6630-5.
123. von der Saal, W., Engh, R.A., Eichinger, A., Gabriel, B., Kucznierz, R., Sauer, J. Synthesis and selective inhibitory activities of terphenyl-bisamidine for serine proteases. Arch Pharm (Weinheim) 1996, 329: 73-82.
124. Takayanagi, M., Sagi, K., Nakagawa, T. et al. Preparation of benzamidine derivatives as anticoagulants. WO 9831661.
125. Klein, S.I., Czekaj, M., Gardner, C.J. et al. Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa. J Med Chem 1998, 41: 437-50.
126. Heran, C., Morgan, S., Kasiewski, C. et al. Antithrombotic efficacy of RPR208566, a factor Xa inhibitor, in a rat model of carotid artery thrombosis. FASEB J 1998, 12: Abst 4151.
127. Maduskuie, T.P., McNamara, K.J., Ru, Y., Knabb, R-M., Stouten, P.F.W. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors. J Med Chem 1998, 41: 53-62.
128. Fevig, J.M., Caccicola, R.S., Alexander, R.S., Knabb, P.M., Stouten, P.F.W., Wexler, R.R. Preparation of meta-amidino-N,N-disubstituted anilines as potent inhibitors of coagulation factor Xa. 215th ACS Natl Meet (Mar 29-Apr 2, Dallas) 1998, MEDI 120.
129. Galemmo, R-A., Maduskuie, T.P., Dominguez, C. et al. The de novo design and synthesis of cyclic urea inhibitors of factor Xa: Initial SAR studies. Bioorg Med Chem Lett 1998, 8: 2705-10.
130. Quan, M.L., Pruit, J.R., Ellis, C.D. et al. Bis-benzamidine isoxazole derivatives as factor Xa inhibitors. Bioorg Med Chem Lett 1997, 7: 2813-8.
131. Pruitt, J.R., Pinto, D.J., Quan, M.L. et al. Isoxazolines and isoxazoles as factor Xa inhibitors. 216th ACS Natl Meet (Aug 23-28, Boston) 1998, MEDI 77.
132. Pruitt, J.R., Fevig, J.M., Quan, M.L, Pinto, D.J. Oxygen or sulfur containing heteroaromatics as factor Xa inhibitors. WO 9828282.
133. Quan, M.L., Wityak, J., Dominguez, C. et al. Biaryl substituted alkylboronate esters as thrombin inhibitors. Bioorg Med Chem Lett 1997, 7: 1595-600.
134. Cheney, D.L. Ewing, W.R., Becker, M. et al. De novo structure-based design of factor Xa inhibitors. SRI 4th Annu Random and Rational Drug Discovery via Combinatorial Chemistry and Structure-Based Design (Sept 15-16, Princeton) 1997.
135. Cheney, D.L., Mason, J.S., Becker, M.R., Ewing, W.R., Pauls, H.W., Todorov, N. De novo structure-based design of factor Xa inhibitors. 215th ACS Natl Meet (Mar 29-Apr 2, Dallas) 1998, MEDI 001.
136. Ewing, W.R., Becker, M.B., Manetta, V. et al. Design of potent and selective, non-covalent inhibitors of factor Xa. 214th ACS Natl Meet (Sept 7-11, Las Vegas) 1997, MEDI 77.
137. Bostwick, J.S., Bentley, R., Morgan, S. et al. RPR120844, a novel, specific inhibitor of coagulation factor Xa inhibits venous thrombus in the rabbit. Thromb Haemost 1999, 81: 157-60.
138. Ewing, W.R., Choi, Y-M., Becker, M. et al. Sulfonamidopyrrolidinones: Design, SAR and parenteral activity of a novel class of factor Xa inhibitors. 215th ACS Natl Meet (Mar 29-Apr 2, Dallas) 1998, MEDI 203.
139. Hauptmann, J. Pharmacology of benzamidine-type thrombin inhibitors. Folia Haematol 1982, 109: 89-97.
140. Fevig, J.M., Quan, M.L. Preparation of amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines as inhibitors of factor Xa. WO 9806694.
141. Dominguez, C., Han, Q., Duffy, D.E. et al. Preparation of amidinoindoles and amidinoazoles as inhibitors of factor Xa and of thrombin. WO 9801428.
142. Preston, J., Stocker, A., Turner, P., Smithers, M.J., Rayner, J.W. Heterocycle derivatives which inhibit factor Xa. WO 9821188.
143. Faull, A., Mayo, C., Preston, J., Stocker, A. Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents. WO 9610022.
144. Smithers, M.J., Preston, J., Stocker, A. Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents. WO 9728129.
145. Illig, C.R., Soll, R.M., Salvino, J.M., Tomczuk, B.E., Subasinghe, N.L. Preparation of arylsulfonylaminobenzenes as factor Xa inhibitors. WO 9640100.
146. Pruitt, J.R., Fevig, J.M., Quan, M.L., Pinto, J.P. Oxygen of sulfur containing heteroaromatics as factor Xa inhibitors. WO 9828282.
147. Pinto, D.J., Pruitt, J.R., Cacciola, J. et al. Nitrogen containing heteroaromatics as factor Xa inhibitors. WO 9828269.
148. Choi-Sledeski, Y.M., Pauls, H.W., Barton, J.N., Ewing, W.R., Green, D.M., Becker, M.R. Preparation of sulfonic acid or sulfonamino N-(heteroaralkyl)-azaheterocyclylamide compounds as inhibitors of factor Xa. WO 9825611.